Skip to content

Allogene Therapeutics ALLO Balance Sheet Statement

FY'25FY'24FY'23FY'22
$61.98M-27.5%$85.51M-8.5%$93.45M+29.4%$72.2M-60.7%
$198.52M-8.6%$217.26M-40.6%$365.54M-19.7%$455.42M+60.4%
$257.75M-15.0%$303.39M-33.9%$459.12M-13.2%$528.82M+12.2%
$72.84M-15.4%$86.06M-13.5%$99.48M-11.8%$112.84M-8.3%
$415.91M-24.2%$548.71M-14.6%$642.84M-21.8%$821.58M-21.8%
$4.27M-20.8%$5.39M-8.5%$5.9M-57.5%$13.89M+35.4%
$32.51M-8.5%$35.52M-4.2%$37.08M-31.0%$53.73M+12.2%
$123.36M-2.5%$126.53M-3.1%$130.6M-15.6%$154.7M+23.1%
400M+188,579%212K+25.4%169K-100.0%400M+100%
-$2.01B-10.5%-$1.82B-16.5%-$1.56B-26.5%-$1.23B-38.1%
$292.54M-30.7%$422.18M-17.6%$512.23M-23.2%$666.88M-27.9%
$415.91M-24.2%$548.71M-14.6%$642.84M-21.8%$821.58M-21.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Allogene Therapeutics's total assets?
Allogene Therapeutics (ALLO) holds $396.0M in total assets, down 22.1% year over year.
How much debt does Allogene Therapeutics have?
Allogene Therapeutics carries $81.1M in total debt against $278.9M of shareholders' equity, a debt-to-equity ratio of 0.29.
How much cash does Allogene Therapeutics have?
Allogene Therapeutics holds $40.6M in cash and equivalents.
Can Allogene Therapeutics cover its short-term obligations?
Its current ratio is 9.65 — current assets exceed current liabilities.
Where does Allogene Therapeutics's balance sheet data come from?
Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.